Search alternatives:
significant substantial » significant potential (Expand Search), significant spatial (Expand Search)
substantial decrease » substantial increase (Expand Search), substantially increased (Expand Search)
significant largest » significantly larger (Expand Search), significant changes (Expand Search), significant aspect (Expand Search)
largest decrease » largest decreases (Expand Search), larger decrease (Expand Search), marked decrease (Expand Search)
Showing 141 - 160 results of 4,793 for search '(( significant largest decrease ) OR ( significant substantial decrease ))', query time: 0.21s Refine Results
  1. 141
    S7 Fig -

    S7 Fig - by Jordan K. Abbott (8934239)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  2. 142
    S6 Fig -

    S6 Fig - by Jordan K. Abbott (8934239)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  3. 143
    S1 Data -

    S1 Data - by Jordan K. Abbott (8934239)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  4. 144
    S13 Fig -

    S13 Fig - by Jordan K. Abbott (8934239)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  5. 145
    S11 Fig -

    S11 Fig - by Jordan K. Abbott (8934239)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  6. 146
    S10 Fig -

    S10 Fig - by Jordan K. Abbott (8934239)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  7. 147
    Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  8. 148
    Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interven... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  9. 149
    Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional pe... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  10. 150
    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  11. 151
    Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  12. 152
    Average purchase costs of 3GCs and all oral antimicrobials per 100 patient-days from Phases 1–4.

    Average purchase costs of 3GCs and all oral antimicrobials per 100 patient-days from Phases 1–4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  13. 153
    Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  14. 154
    S1 Dataset -

    S1 Dataset - by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  15. 155
    Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phas... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  16. 156
    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  17. 157
    Pop-up for oral 3GC prescription.

    Pop-up for oral 3GC prescription. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  18. 158
    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  19. 159
    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  20. 160
    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:

Search Tools: